CARLSBAD, Calif. & LYON, France--(BUSINESS WIRE)--Dec. 15, 2005--Invitrogen Corporation (Nasdaq:IVGN), a provider of essential life science technologies for disease research and drug discovery and genOway, a creator of genetically modified biological models today announced the signing of a co-marketing agreement around RNAi related services. Under the terms of the agreement, Invitrogen and genOway will combine Invitrogen’s expertise in RNAi research technologies with genOway’s portfolio of transgenesis technologies and RNAi in vivo experience to create a services platform offering RNAi vector design through the creation of RNAi transgenic rodent models. Both companies will share revenues but specific financial terms of the collaboration were not disclosed.
